Eli Lilly is acquiring three vaccine developers for up to $3.8B, pushing into infectious disease as a strategic diversification from its GLP-1/diabetes dominance. The deal is modest relative to Lilly's ~$1T market cap but signals a pipeline pivot that could re-rate sentiment if vaccine assets de-risk over the next 12-18 months.